Blue Jet Healthcare Limited — Investor Meet, 13-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Blue Jet Healthcare's Q3 FY26 revenue grew 16% QoQ to Rs 192.4 Cr (EBITDA Rs 46.9 Cr, PAT Rs 40.2 Cr). Profits declined QoQ due to product mix and a one-time inventory write-off. YoY, Q3 revenue fell 40% with significant profit drops from lower Pharma Intermediates and Artificial Sweeteners sales amid de-stocking. For 9M FY26, revenue rose 3% YoY to Rs 712.7 Cr, while EBITDA and PAT decreased 6%. The company is strategically expanding, acquiring land in Vizag and establishing a Hyderabad R&D center. Focus remains on advanced Contrast Media intermediates and niche CDMO services, indicating a long-term growth view despite recent profit challenges.